BSX vs LMAT: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
BSX is the larger of the two ($63.41B market cap): the incumbent the market prices for continued execution (13.97x forward earnings, beta 0.58). LMAT is the smaller challenger ($1.81B), actually pricier on forward earnings (25.12x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
BSX vs LMAT: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | BSX | LMAT | What it tells you |
|---|---|---|---|
| Market cap | $63.41B | $1.81B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 13.97 | 25.12 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 18.46 | 28.77 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.58 | 0.49 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 6% of range | 2% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 2.47 | 4.19 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: BSX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how BSX and LMAT affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BSX and LMAT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BSX and LMAT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Boston Scientific Corporation (BSX) do?
Boston Scientific Corporation is a Marlborough, Massachusetts-based medical device company that develops, manufactures, and markets minimally invasive devices used in interventional cardiology, electrophysiology, structural heart, peripheral interventions, endoscopy, urology, neuromodulation, and cardiac rhythm management. It reports through two broad segments: Cardiovascular, which houses the electrophysiology business (led by the Farapulse pulsed field ablation system) and the Watchman left-atrial-appendage closure franchise, and MedSurg, which spans endoscopy, urology, and neuromodulation. The company sells into hospitals and physicians across roughly 130 countries and competes at the leading edge of catheter-based and device-based procedures that substitute for more invasive surgery.
What does LeMaitre Vascular (LMAT) do?
LeMaitre Vascular, founded in 1983 by vascular surgeon George LeMaitre, sells the unglamorous hardware of open vascular surgery: biologic patches, bovine carotid artery grafts sold as Artegraft, human vascular and cardiac allografts, carotid shunts, valvulotomes, embolectomy catheters and synthetic grafts. Roughly 163 direct sales representatives call on vascular surgeons in hospitals, which is the whole point of the model. Individual products are small line items with low average selling prices, too minor for a Medtronic or a Boston Scientific to defend aggressively, so LeMaitre buys niche lines (Restore Flow allografts in 2016 for ~$14M, Artegraft in 2020 for ~$90M), pushes them through its own rep force, and raises prices steadily.
BSX vs LMAT: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- BSX drivers: Farapulse and the Pulsed Field Ablation Wave; Watchman Franchise Expansion.
- LMAT drivers: Price, not volume, is the growth engine; Artegraft going international.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The most immediate concern is a run of setbacks in 2026. For LMAT, cardiac allograft growth is limited by donor tissue supply, and management is prioritizing US supply before international expansion, so that line stays capacity-bound into the second half of 2026.
BSX or LMAT: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BSX if you believe its drivers more; LMAT if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BSX and LMAT guides.
BSX vs LMAT: the full fundamentals
BSX. Boston Scientific's trailing P/E of roughly 18x and forward multiple near 13x are far below the sustained premium the stock carried during its high-growth phase. The compression followed a decline of about 55% over the past year, while the S&P 500 rose about 17%, driven by slowing growth, repeated outlook cuts, and the September cybersecurity disruption. Third-quarter results are due October 28, 2026, with consensus near $0.74 to $0.76 of adjusted EPS on revenue of about $5.1 billion, and the analyst mean target of about $59 sits well above the $44.06 share price, so the debate is whether the lower multiple reflects fair concern about decelerating growth or an over-correction.
LMAT. At $81.89 a share on October 16, 2026 and a ~$1.87B market value, LMAT carries about 7.1 times trailing sales and roughly 6.4 times sales net of its ~$204M net cash position, with a trailing P/E near 29 and a forward P/E near 26. Those are software-adjacent multiples on a $262M revenue base, sustained by 72% gross margins and a two-decade record of annual price increases rather than by growth (organic growth is guided to ~11%). The de-rating from a ~$118 high to within a few dollars of the 52-week low of ~$78.22 happened on a ~$1.1M revenue miss, an EPS miss and a one-point cut to the organic target, which is a measure of how tightly the valuation was tied to the pricing story holding. Seven covering analysts carry a mean target near $107.
Headline figures (approximate, October 2026): BSX shows revenue (ttm) ~$21 billion (+7.5% YoY in Q2 2026), revenue (fy 2025) ~$20.1 billion, net income (ttm) ~$3.7 billion (profit margin ~17.5%), adjusted eps (q2 2026) $0.86 vs $0.83 est.; LMAT shows revenue (ttm) ~$262M, up ~10% year over year in Q2 2026, q2 2026 sales ~$70.4M, ~10% organic (~7% price, ~3% volume), q2 2026 eps vs estimate ~$0.74 vs ~$0.81 consensus, gross / operating margin (ttm) ~71.9% / ~29%.
The bottom line: BSX vs LMAT
BSX and LMAT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BSX and LMAT exposure against your real portfolio. It is not an investment adviser.
Wondering how BSX or LMAT fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Boston Scientific Corporation
Ask Walnut's AI anything about BSX and see how it fits what you own.
FAQ
What is the difference between BSX and LMAT?
+
Boston Scientific Corporation is a Marlborough, Massachusetts-based medical device company that develops, manufactures, and markets minimally invasive devices used in interventional cardiology, electrophysiology, structural heart, peripheral interventions, endoscopy, urology, neuromodulation, and cardiac rhythm management. LeMaitre Vascular, founded in 1983 by vascular surgeon George LeMaitre, sells the unglamorous hardware of open vascular surgery: biologic patches, bovine carotid artery grafts sold as Artegraft, human vascular and cardiac allografts, carotid shunts, valvulotomes, embolectomy catheters and synthetic grafts. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is BSX or LMAT the better stock?
+
Neither is universally better. BSX is the larger incumbent; LMAT is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, BSX or LMAT?
+
On forward P/E (as of November 2026), BSX trades at 13.97x and LMAT at 25.12x, so BSX is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both BSX and LMAT?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of BSX vs LMAT?
+
BSX: The most immediate concern is a run of setbacks in 2026. Management lowered its profit outlook in July on weaker Watchman demand and US electrophysiology share losses, then in September said a cybersecurity incident had disrupted manufacturing and order shipments and that it was unlikely to meet its third-quarter and full-year sales and adjusted earnings forecasts. In October it recalled 262,686 Imager II angiographic catheters because the tip may fracture or detach during use, a reminder of the product-recall and safety-signal risk inherent to medical devices. Competition is intensifying as Medtronic and Johnson and Johnson scale their own pulsed field ablation systems, which could further erode Boston Scientific's early PFA share and pressure pricing. Brokers including Baird, Truist and Mizuho trimmed price targets in mid-October 2026. Foreign exchange swings, hospital capital-spending cycles, reimbursement or regulatory changes, about $12.6 billion of debt, and integration risk from the company's acquisition strategy each add uncertainty. LMAT: Cardiac allograft growth is limited by donor tissue supply, and management is prioritizing US supply before international expansion, so that line stays capacity-bound into the second half of 2026. The North Brunswick, New Jersey facility, where the Artegraft graft that now carries ~21% of sales is processed, received additional FDA quality-system observations on June 25, 2026, with a company response filed July 16; an escalation there would reach a large share of revenue. Separately, an FDA pre-submission indicated a clinical trial is likely to be required for the QuickStitch product, on timelines measured in years, and catheter sales fell ~11% against a prior-year period inflated by post-recall stocking orders. Currency, Middle East export disruption and the tissue constraint each accounted for roughly a third of the Q2 revenue shortfall and are expected to persist through the second half. The convertible notes convert near ~$119 to ~$120 per share, which caps upside participation with dilution above that level; as of the latest filings reviewed for this page no filed securities class action, restatement or going-concern matter appears in the company's filings, and the stock's ~28 times guided 2026 earnings (about 26 times 2027 estimates) leaves limited room if pricing power narrows. The September quarter is also a seasonally soft comparison: consensus of ~$0.69 EPS for the November 4 report is below the ~$0.75 of the year-earlier quarter, so a second consecutive miss would land on a stock that has already de-rated.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BSX or LMAT; figures are approximate and dated (as of November 2026). Verify current data before investing.